Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s stock price fell 3.5% during mid-day trading on Monday . The stock traded as low as C$2.87 and last traded at C$2.90. 922 shares changed hands during trading, a decline of 88% from the average session volume of 7,410 shares. The stock had previously closed at C$3.00.
Eupraxia Pharmaceuticals Stock Performance
The firm has a 50-day moving average of C$3.16 and a 200-day moving average of C$2.85.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Recommended Stories
- Five stocks we like better than Eupraxia Pharmaceuticals
- What is a Low P/E Ratio and What Does it Tell Investors?
- How to Invest in Small Cap Stocks
- Growth Stocks: What They Are, Examples and How to Invest
- These Are the Dividend Stocks Insiders Bought in January
- Why Invest in 5G? How to Invest in 5G Stocks
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
